Annual report pursuant to Section 13 and 15(d)

Non-controlling Interest (Details)

v3.22.0.1
Non-controlling Interest (Details) - USD ($)
12 Months Ended
Sep. 05, 2018
Sep. 05, 2018
Dec. 31, 2021
Dec. 31, 2020
Noncontrolling Interest        
Equity Method Investment, Ownership Percentage     83.00%  
Related Party Transaction, Expenses from Transactions with Related Party $ 328,000      
Research and Development Expense     $ 7,800,000 $ 5,131,000
Fair Value Of Shares Issued   $ 285,000    
Net Income (Loss) Attributable to Noncontrolling Interest     (1,000) (73,000)
Stock Purchase Agreement [Member]        
Noncontrolling Interest        
Research and Development Expense     $ 1,000 225,000
SYN Biomics [Member]        
Noncontrolling Interest        
Equity Method Investment, Ownership Percentage 88.50% 88.50% 100.00%  
Equity interest by parent 11.50% 11.50%    
Net Income (Loss) Attributable to Noncontrolling Interest       2,800,000
Synthetic Biomics Inc [Member]        
Noncontrolling Interest        
Equity interest by parent     17.00%  
Dr. Pimentels [Member]        
Noncontrolling Interest        
Net Income (Loss) Attributable to Noncontrolling Interest       73,000,000,000
Dr. Pimentels [Member] | Consolidation, Eliminations        
Noncontrolling Interest        
Net Income (Loss) Attributable to Noncontrolling Interest       $ 505,000
Cedarssinai Medical Center [Member]        
Noncontrolling Interest        
Number Of Common Stock To Be Issued 50,000 50,000    
Number Of Common Stock To Be Held By Related Party 7,480,000 7,480,000    
Cedarssinai Medical Center [Member] | SYN Biomics [Member]        
Noncontrolling Interest        
Additional Number Of Common Stock To Be Issued 2,420,000 2,420,000    
Cedarssinai Medical Center [Member] | Synthetic Biomics Inc [Member]        
Noncontrolling Interest        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 17.00% 17.00%